Actinium Pharmaceuticals (NYSE:ATNM) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Actinium Pharmaceuticals (NYSE:ATNM) from a sell rating to a hold rating in a report published on Friday.

Separately, HC Wainwright reiterated a “buy” rating and issued a $4.00 price objective on shares of Actinium Pharmaceuticals in a report on Tuesday, April 1st. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $7.40.

Actinium Pharmaceuticals Trading Down 3.2 %

Actinium Pharmaceuticals stock opened at $1.21 on Friday. The stock has a market cap of $37.75 million, a P/E ratio of -0.87 and a beta of -0.27. The company has a fifty day simple moving average of $1.28 and a 200-day simple moving average of $1.39. Actinium Pharmaceuticals has a 12-month low of $1.03 and a 12-month high of $10.24.

Institutional Trading of Actinium Pharmaceuticals

Large investors have recently made changes to their positions in the company. Squarepoint Ops LLC lifted its stake in Actinium Pharmaceuticals by 25.4% in the fourth quarter. Squarepoint Ops LLC now owns 183,262 shares of the company’s stock valued at $231,000 after buying an additional 37,159 shares during the last quarter. Nuveen Asset Management LLC increased its holdings in shares of Actinium Pharmaceuticals by 49.5% in the 4th quarter. Nuveen Asset Management LLC now owns 148,560 shares of the company’s stock valued at $187,000 after acquiring an additional 49,214 shares during the period. Deutsche Bank AG raised its position in Actinium Pharmaceuticals by 413.6% in the 4th quarter. Deutsche Bank AG now owns 123,134 shares of the company’s stock valued at $155,000 after purchasing an additional 99,158 shares during the last quarter. Bank of America Corp DE raised its position in Actinium Pharmaceuticals by 76.6% in the 4th quarter. Bank of America Corp DE now owns 78,767 shares of the company’s stock valued at $99,000 after purchasing an additional 34,176 shares during the last quarter. Finally, Northern Trust Corp boosted its stake in Actinium Pharmaceuticals by 4.9% during the 4th quarter. Northern Trust Corp now owns 251,930 shares of the company’s stock worth $317,000 after purchasing an additional 11,812 shares during the period. 27.50% of the stock is owned by institutional investors and hedge funds.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).